1 hr. ago
Qiagen N.V. (NYSE:QGEN) announced on August 10 that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, marking the company's first entry into the U.S. bloodstream infection testing market. Operating on the QIAstat-Dx platform, which boasts over 5,200 global placements, the automated panel detects 20 gram-positive bacterial and fungal targets, alongside 10 genetic antimicrobial resistance markers, in about one hour.
This regulatory milestone comes shortly after Qiagen N.V. (NYSE:QGEN) reported solid Q2 2026 financial results on August 5. Net sales reached $535 million (flat YoY at constant exchange rates), beating guidance for a 2% decline. Adjusted diluted EPS rose 3% YoY to $0.62, topping expectations. Performance across core growth pillars (+5% CER), including Sample Technologies (+9% CER) and QIAcuity digital PCR, helped offset a 7% drop in QIAstat-Dx respiratory testing sales. QGEN reaffirmed its full-year 2026 outlook for 1%–2% CER net sales growth and adjusted EPS of at least $2.43.
Additionally, Qiagen announced that Jonathan Pratt will take over as CEO effective September 1, succeeding Thierry Bernard. Joining at a pivotal time, Pratt will lead executive execution following an intensive portfolio evaluation and ongoing corporate efficiency programs.
This brings up a key question: Does the FDA clearance and steady execution under incoming leadership position Qiagen N.V. (NYSE:QGEN) for a valuation rerating, or will soft regional demand and product mix headwinds keep shares range-bound?
Bulls argue that Qiagen's high-margin, consumable-driven business model (comprising 90% of total Q2 sales) provides defensive recurring cash flow, generating $301 million in H1 operating cash flow. The new FDA approval expands QIAstat-Dx into its fourth major infectious disease area in the U.S., unlocking higher-margin hospital diagnostic channels. Furthermore, solid growth across core pillars like Sample Technologies and QIAcuity demonstrates fundamental demand. Strong internal cash generation also gives incoming CEO Jonathan Pratt ample balance sheet capacity to pursue disciplined capital deployment and portfolio innovation.
#qiagen
This regulatory milestone comes shortly after Qiagen N.V. (NYSE:QGEN) reported solid Q2 2026 financial results on August 5. Net sales reached $535 million (flat YoY at constant exchange rates), beating guidance for a 2% decline. Adjusted diluted EPS rose 3% YoY to $0.62, topping expectations. Performance across core growth pillars (+5% CER), including Sample Technologies (+9% CER) and QIAcuity digital PCR, helped offset a 7% drop in QIAstat-Dx respiratory testing sales. QGEN reaffirmed its full-year 2026 outlook for 1%–2% CER net sales growth and adjusted EPS of at least $2.43.
Additionally, Qiagen announced that Jonathan Pratt will take over as CEO effective September 1, succeeding Thierry Bernard. Joining at a pivotal time, Pratt will lead executive execution following an intensive portfolio evaluation and ongoing corporate efficiency programs.
This brings up a key question: Does the FDA clearance and steady execution under incoming leadership position Qiagen N.V. (NYSE:QGEN) for a valuation rerating, or will soft regional demand and product mix headwinds keep shares range-bound?
Bulls argue that Qiagen's high-margin, consumable-driven business model (comprising 90% of total Q2 sales) provides defensive recurring cash flow, generating $301 million in H1 operating cash flow. The new FDA approval expands QIAstat-Dx into its fourth major infectious disease area in the U.S., unlocking higher-margin hospital diagnostic channels. Furthermore, solid growth across core pillars like Sample Technologies and QIAcuity demonstrates fundamental demand. Strong internal cash generation also gives incoming CEO Jonathan Pratt ample balance sheet capacity to pursue disciplined capital deployment and portfolio innovation.
#qiagen
15 days ago
Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company's own outlook. For a diagnostics and life sciences supplier still working through the loss of discontinued product lines, beating a cautious bar is one thing. What happens next, as management leans on a stack of new launches to carry the back half of the year, is the more interesting question.
The company's so-called growth pillars, the businesses management is counting on to outpace the broader market, expanded 5% at constant exchange rates in the quarter. Sample Technologies led with 9% CER growth, driven by automated consumables and higher instrument sales. QIAcuity, the digital PCR platform, posted double-digit consumables growth even as weaker OEM demand offset some of that strength. QuantiFERON, the tuberculosis test that had flagged a sharp drop in US immigration testing demand back in the first quarter, still managed to return to growth as demand across other testing groups more than made up the difference.
Behind those numbers sits a wave of product activity. QIAsymphony Connect launched commercially, QIAsprint Connect placements are drawing what management called strong pharma customer acceptance, and two new bloodstream infection panels for QIAstat launched in Europe, detecting 33 pathogens and 28 resistance markers in about an hour, with US FDA approval targeted by year-end. Parse, the single-cell ****** ysis business, is running ahead of its roughly $40 million 2026 sales target and was selected for a NASA-supported research program aboard the International ****** e Station. Qiagen also completed a $500 million share repurchase in January and raised its annual dividend 40% to $0.35 per share.
The flat top line masks uneven performance underneath. Diagnostic solutions overall declined 2% at constant currency, and PCR and nucleic acid amplification sales fell 8%, with QIAstat-Dx down 7% as a tough prior-year comparison in respiratory testing outweighed gains in gastrointestinal and meningitis panels. Profitability also gave ground. Adjusted operating income fell 2% to $157 million, with the margin slipping to 29.4% from 29.9% a year earlier, and adjusted gross margin declined to 66.2% from 66.7% on product mix shifts.
Regionally, EMEA sales fell 2% CER as declines in Germany, France, and Italy outweighed gains elsewhere, and Asia Pacific sales fell 2% CER as China dropped in the low teens, even though it improved sequentially. Inventory days outstanding also climbed to 153 from 149, tied to stockpiling ahead of new launches. The company is now guiding to a jump from roughly negative 1% CER sales growth in the first half to 3% to 4% in the second half, a swing that leans heavily on new products, easier comparisons and the fading drag from discontinued lines all landing on schedule.
#Growth #adjusted #ro
The company's so-called growth pillars, the businesses management is counting on to outpace the broader market, expanded 5% at constant exchange rates in the quarter. Sample Technologies led with 9% CER growth, driven by automated consumables and higher instrument sales. QIAcuity, the digital PCR platform, posted double-digit consumables growth even as weaker OEM demand offset some of that strength. QuantiFERON, the tuberculosis test that had flagged a sharp drop in US immigration testing demand back in the first quarter, still managed to return to growth as demand across other testing groups more than made up the difference.
Behind those numbers sits a wave of product activity. QIAsymphony Connect launched commercially, QIAsprint Connect placements are drawing what management called strong pharma customer acceptance, and two new bloodstream infection panels for QIAstat launched in Europe, detecting 33 pathogens and 28 resistance markers in about an hour, with US FDA approval targeted by year-end. Parse, the single-cell ****** ysis business, is running ahead of its roughly $40 million 2026 sales target and was selected for a NASA-supported research program aboard the International ****** e Station. Qiagen also completed a $500 million share repurchase in January and raised its annual dividend 40% to $0.35 per share.
The flat top line masks uneven performance underneath. Diagnostic solutions overall declined 2% at constant currency, and PCR and nucleic acid amplification sales fell 8%, with QIAstat-Dx down 7% as a tough prior-year comparison in respiratory testing outweighed gains in gastrointestinal and meningitis panels. Profitability also gave ground. Adjusted operating income fell 2% to $157 million, with the margin slipping to 29.4% from 29.9% a year earlier, and adjusted gross margin declined to 66.2% from 66.7% on product mix shifts.
Regionally, EMEA sales fell 2% CER as declines in Germany, France, and Italy outweighed gains elsewhere, and Asia Pacific sales fell 2% CER as China dropped in the low teens, even though it improved sequentially. Inventory days outstanding also climbed to 153 from 149, tied to stockpiling ahead of new launches. The company is now guiding to a jump from roughly negative 1% CER sales growth in the first half to 3% to 4% in the second half, a swing that leans heavily on new products, easier comparisons and the fading drag from discontinued lines all landing on schedule.
#Growth #adjusted #ro
